S-8 1 d740071ds8.htm S-8 S-8

As filed with the Securities and Exchange Commission on January 24, 2024

Registration No. 333-            

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM S-8

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

 

PMV PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   46-3218129
(State or other jurisdiction of
incorporation or organization)		   (I.R.S. Employer
Identification Number)

One Research Way

Princeton, NJ 08540

(609) 642-6670

(Address, including zip code, and telephone number, including area code, of Registrant’s principal executive offices)

 

 

2020 Equity Incentive Plan

2020 Employee Stock Purchase Plan

(Full title of the plan)

 

 

David H. Mack, Ph.D.

President and Chief Executive Officer

PMV Pharmaceuticals, Inc.

One Research Way

Princeton, NJ 08540

(609) 642-6670

(Name, address, including zip code, and telephone number, including area code, of agent for service)

 

 

Copies to:

 

Kenneth A. Clark

Tony Jeffries
Megan J. Baier
Wilson Sonsini Goodrich & Rosati, P.C.

1301 Avenue of the Americas

New York, NY 10019
(212) 999.5800

  

Michael Carulli
Chief Financial Officer
PMV Pharmaceuticals, Inc.
One Research Way

Princeton, NJ 08540

(609) 642-6670

 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer   ☐    Accelerated filer   ☐
Non-accelerated filer   ☐ (Do not check if a smaller reporting company)    Smaller reporting company   ☒
     Emerging growth company   ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐

 

 

 

REGISTRATION OF ADDITIONAL SHARES PURSUANT TO GENERAL INSTRUCTION E

This Registration Statement is being filed with the Securities and Exchange Commission (the “Commission”) for the purpose of registering additional securities of the same class as other securities for which a registration statement of PMV Pharmaceuticals, Inc. (the “Registrant”) on Form S-8 relating to the same employee benefit plans is effective. The number of the Registrant’s common stock available for grant and issuance under the 2020 Equity Incentive Plan (“2020 Plan”) is subject to annual increase on the first day of each fiscal year beginning with fiscal year 2021, in an amount equal to the least of (i) 4,406,374 shares, (ii) five percent (5%) of the outstanding shares of the Registrant’s common stock on the last day of the immediately preceding fiscal year or (iii) such number of shares determined by the 2020 Plan administrator. The number of the Registrant’s common stock available for grant and issuance under the 2020 Employee Stock Purchase Plan (“2020 ESPP”) is subject to annual increase on the first day of each fiscal year beginning with fiscal year 2021 equal to the least of (i) 801,504 shares, (ii) one percent (1%) of the outstanding shares of the Registrant’s common stock on the last day of the immediately preceding fiscal year or (iii) such number of shares determined by the 2020 ESPP administrator. On January 1, 2024, the number of shares of the Registrant’s common stock available for grant and issuance under the 2020 Plan and available for issuance under the 2020 ESPP increased by 2,572,174 shares and 514,434 shares, respectively. This Registration Statement registers such additional shares of the Registrant’s common stock.

The Registrant previously registered shares of common stock for issuance under the 2020 Plan and the 2020 ESPP pursuant to (i) a registration statement on Form S-8 (File No. 333-249094) filed with the Commission on September 28, 2020, (ii) a registration statement on Form S-8 (File No. 333-256346) filed with the Commission on May 21, 2021, and (iii) a registration statement on Form S-8 (File No. 333-262308) filed with the Commission on January 24, 2022 and (iv) a registration statement on Form S-8 (File No. 333-269394) filed with the Commission on January 25, 2023 ((i), (ii), (iii) and (iv), collectively, the “Prior Registration Statements”). In accordance with General Instruction E to Form S-8, the contents of the Prior Registration Statements are hereby incorporated by reference. In accordance with the instructional note to Part I of Form S-8 promulgated by the Commission, the information specified by Part I of Form S-8 has been omitted from this Registration Statement.

PART II

INFORMATION REQUIRED IN REGISTRATION STATEMENT

 

Item 3.

Incorporation of Documents by Reference.

The Registrant hereby incorporates by reference into this Registration Statement the following documents previously filed with the Commission:

(1) The Registrant’s Registration Statements on Form S-8 previously filed with the Commission on September 28, 2020 (File No.  333-249094), May 21, 2021 (File No.  333-256346), January 24, 2022 (File No. 333-262308) and January 25, 2023 (File No.  333-269394);

(2) The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022 (the “2022 Form 10-K”), filed with the Commission on March 1, 2023 (File No. 001-39539);

(3) The information specifically incorporated by reference into the 2022 Form 10-K from the Registrant’s definitive proxy statement on Schedule 14A filed with the Commission on April 28, 2023 (File No. 001-39539);

(4) The Registrant’s Quarterly Report on Form 10-Q for the quarter ended March  31, 2023, filed with the Commission on May 10, 2023, the Registrant’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2023, filed with the Commission on August 9, 2023 and the Registrant’s Quarterly Report on Form 10-Q for the quarter ended September  30, 2023, filed with the Commission on November 9, 2023;

(5) The Registrant’s Current Reports on Form 8-K filed with the Commission on April 28, 2023, June 9, 2023, October  12, 2023, January 5, 2024 and January  18, 2024 (other than information furnished rather than filed);

(6) The description of the Registrant’s common stock contained in a registration statement on Form 8-A (File No. 001-39539), filed with the Commission on September 21, 2020, pursuant to Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as updated by the description of the Registrant’s common stock contained in Exhibit 4.1 to the Registrant’s Annual report on Form 10-K for the fiscal year ended December 31, 2020, filed with the Commission on March 3, 2021, including any amendment or report filed for the purpose of updating such description; and

(7) All documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered have been sold or that deregisters all securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such documents; provided, however, that documents or information deemed to have been furnished and not filed in accordance with the rules of the Commission shall not be deemed incorporated by reference into this Registration Statement. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

 

Item 8.

Exhibits.

 

          Incorporated by Reference  

Exhibit
Number

   

Description

    Form      File No.      Exhibit      Filing Date  
    4.1    Amended and Restated Certificate of Incorporation of the Registrant      8-K        001-39539        3.1        9/29/2020  
    4.2    Amended and Restated Bylaws of the Registrant      10-Q        001-39539        3.3        5/10/2023  
    4.3    Specimen common stock certificate of the Registrant      S-1/A        333-248627        4.2        9/21/2020  
    5.1*    Opinion of Wilson Sonsini Goodrich & Rosati, Professional Corporation            
  23.1*    Consent of Independent Registered Public Accounting Firm            
  23.2*    Consent of Wilson Sonsini Goodrich & Rosati, Professional Corporation (contained in Exhibit 5.1 hereto)            
  24.1*    Power of Attorney (contained on signature page hereto)            
  99.1    2020 Equity Incentive Plan and forms of agreements thereunder      S-1/A        333-248627        10.3        9/21/2020  
  99.2    2020 Employee Stock Purchase Plan and forms of agreements thereunder      S-1/A        333-248627        10.4        9/21/2020  
107*    Calculation of Filing Fee Table            

 

*

Filed herewith.

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement on Form S-8 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Princeton, New Jersey, on January 24, 2024.

 

PMV PHARMACEUTICALS, INC.
By:  

/s/ David H. Mack

  David H. Mack, Ph.D.
  President and Chief Executive Officer

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints David H. Mack, Ph.D. and Michael Carulli as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and substitution, for him or her and in their name, place and stead, in any and all capacities, to sign this Registration Statement and any and all amendments thereto (including post-effective amendments), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact, and agents or any of them, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this registration statement on Form S-8 has been signed by the following persons in the capacities and on the dates indicated.

 

Signature

   

Title

  

Date

/s/ David H. Mack

David H. Mack, Ph.D.

   

President, Chief Executive Officer and Director

(Principal Executive Officer)

   January 24, 2024

/s/ Michael Carulli

Michael Carulli

   

Chief Financial Officer

(Principal Financial and Accounting Officer)

   January 24, 2024

/s/ Richard Heyman

Richard Heyman, Ph.D.

   

Chair of the Board

   January 24, 2024

/s/ Charles M. Baum

Charles M. Baum, M.D., Ph.D.

   

Director

   January 24, 2024

/s/ Arnold Levine

Arnold Levine, Ph.D.

   

Director

   January 24, 2024

/s/ Carol Gallagher

Carol Gallagher, Pharm.D.

   

Director

   January 24, 2024

/s/ Laurie Stelzer

Laurie Stelzer

   

Director

   January 24, 2024

/s/ Kirsten Flowers

Kirsten Flowers

   

Director

   January 24, 2024